Erasca, Inc. (ERAS:NASDAQ) closed at $14.99 on October 26, 2026, up 4.17% on the day. The stock trades 38.3% below its 52-week high of $24.28 and 612.1% above its 52-week low of $2.11. Over the past year, it gained 527.2%. Erasca, Inc. is part of the Health Care sector.
In 252 trading sessions since October 24, 2025, ERAS closed higher on 134 days (53%). Its best day was January 7, 2026 (+42.42%) and its worst was April 28, 2026 (-48.30%). The stock moved 10% or more in a single session 18 times.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes two clinical-stage programs (ERK and SHP2 inhibitors), two preclinical-stage programs (CNS-penetrant KRAS G12C and EGFR inhibitors), and seven discovery-stage programs targeting other key oncogenic drivers.
Find more stocks like ERAS with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.